Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase IIb |
| Species: | Human |
| Stage: | Primary analysis complete |
| Study Start Date: | 2007-01-12 |
| Study Made Public: | NA |
Title
A multicenter double-blind randomized placebo-controlled Phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa
Description
HVTN 503 (Phambili) is a Phase IIb clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag/pol/nef (Ad5).
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.